Profile #1648
Profile #1648 - Immunotope - Belgium
Date: 2007/06/25
Deadline: 2010/03/31
Contact
Organisation
Immunotope
Contact
person
von Hoegen, Dr. Paul
Email
PvonHoegen@immunotope.com
Address
Route de Renipont 25a
Postcode
1380
Country
Belgium
Telephone
+32 475913572
Department
City
Fax
Website
Organisation
Type:
Companies & Enterprises
Is a Small and Medium Sized Enterprise (SME)? YES
Number of
Employees
10
Lasne - Brussels
Description of
research
activity:
IMMUNOTOPE is a clinical stage biotechnology company developing immunotherapy
products for the treatment and prevention of cancer and chronic viral
infections. Our products activate the patient’s own immune system to fight disease
and prevent recurrence. Our comprehensive approach to cancer therapy focuses on
the critical, unmet need to diagnose cancer at the very earliest stages and to
develop effective treatments that destroy tumors and prevent metastasis. Our
product portfolio includes ovarian, breast and colon cancer and
hepatitis.
Immunotope's platform provides the ideal combination of technologies for successful
immunotherapy. We are developing products and services that will:
Address the need for highly efficacious, curative treatments with minimal toxicity
Use the exquisite sensitivity and specificity of the immune system for early
detection of cancer
Provide innovative tools and services for collaborative development of novel drug
and diagnostic products
Provide our shareholders with exceptional returns on their investment
We use proprietary immunoproteomics technologies to identify naturally processed
and presented antigens associated with Major Histocompatibility Complex Class I
and Class II molecules that are present only on diseased cells. Immunotope’s lead
product is the OCPM Immunotherapeutic Vaccine, a multivalent cancer therapeutic
mixture of twelve different novel antigens, each of which targets a separate, critical
pathway known to be present in highly aggressive tumors. An Investigational New
Drug application (IND) for a Phase I clinical trial in ovarian cancer patients has been
cleared by FDA, with an amendment to add a cohort of breast cancer patients under
FDA review. The trial is being conducted at the Duke University Comprehensive
Cancer Center.
Immunotope is also applying its platform technology to develop novel autoantibodybased biomarkers for early-stage detection of cancer. Performed as a simple blood
test, our products will be rapid, non-invasive and indication-specific early-stage
cancer diagnostics.
We are developing the theranostic uses of the subset of autoantigens that are
autoantibody-reactive and MHC-processed and presented, for combination
diagnostic and therapeutic application.
Former participation in an FP European
project? YES
Project title / Acronym:
HIV vaccines, Oncology
Activities performed::
Project coordination,
Immune analysis
partnering
Industrial partner
Reviewer of proposals for the EU
Research topics
• HEALTH-2007-1.1-4: SME-driven collaborative research projects for developing tools and technologies
for high-throughput research
• HEALTH-2007-1.2-5: Standardisation and improvement of pre-analytical procedures for in vitro
diagnostics.
• HEALTH-2007-2.4.1-10: Role of inflammation in tumour initiation and progression.
• HEALTH-2007-2.4.1-11: Epidemiology of gene-environment interactions involved in carcinogenesis.
• HEALTH-2007-2.4.1-9: Innovative combination clinical trials for multimodal cancer therapy.
Expertise/commitment offered
Keywords
specifying the
expertise:
Vaccines, Oncology, technology tranfer, pre-clinic to clinic, academia -SMEIndustry
Description of the
expertise:
Immunoproteomics Services for Antigen Discovery and Characterization
We offer a range of services that use our proprietary antigen identification and
immunoproteomics technologies to identify panels of naturally processed MHC
Class I and Class II-associated peptides for customer-specified indications.
The products of our analysis include MHC-processed antigens for development
of immunotherapeutic vaccines, antibody targets and diagnostics.
Our technology platform can be applied to the identification of antigens for
cancer, infectious diseases, autoimmune disorders and bacterial and fungal
diseases where MHC processing and presentation of antigens is critical to
eliciting a protective immune response.
We have expertise in autoantigen identification and screen serum
autoantibodies to identify novel diagnostic and antibody therapeutic targets.
Our services also include:
Analysis of MHC processing of proteins in genetic constructs
Analysis of antigen specificity post cell-based immunotherapies
Commitment
offered
Research,Demonstration,Dissemination
Expectations
Term
commitment:
Medium (1 to 3 years)
Expected results
for your
organisation:
Involvement in projects,
peptide technology knowledge to add to consortium
gain of diesease specific knowledge
long term collaborations in caner and infectious disease